

Global Hospital-acquired Pneumonia(HAP) Drugs Market Growth 2022-2028

https://marketpublishers.com/r/GDEF950EF246EN.html

Date: February 2022 Pages: 106 Price: US\$ 3,660.00 (Single User License) ID: GDEF950EF246EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Hospital-acquired Pneumonia(HAP) Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Hospital-acquired Pneumonia(HAP) Drugs market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Hospital-acquired Pneumonia(HAP) Drugs market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Hospital-acquired Pneumonia(HAP) Drugs market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Hospital-acquired Pneumonia(HAP) Drugs market, reaching US\$ million by the year 2028. As for the Europe Hospital-acquired Pneumonia(HAP) Drugs landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Hospital-acquired Pneumonia(HAP) Drugs players cover Pfizer, GlaxoSmithKline, Merck, and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Hospital-acquired Pneumonia(HAP) Drugs market by product type, application, key manufacturers and key regions and countries.



Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6

Antibacterial

Antiviral

Antifungal

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Hospitals

Clinics

Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea



Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

Pfizer

GlaxoSmithKline



Merck

Mylan

Novartis

Teva Pharmaceutical Industries

AstraZeneca

Arsanis

Combioxin

Shinogi

Sun Pharmaceutical Industries

The Medicines Company

Theravance Biopharma



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
- 2.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Hospital-acquired Pneumonia(HAP) Drugs by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Hospital-acquired Pneumonia(HAP) Drugs by Country/Region, 2017, 2022 & 2028

2.2 Hospital-acquired Pneumonia(HAP) Drugs Segment by Type

2.2.1 Antibacterial

- 2.2.2 Antiviral
- 2.2.3 Antifungal

2.3 Hospital-acquired Pneumonia(HAP) Drugs Sales by Type

2.3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2022)

2.3.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue and Market Share by Type (2017-2022)

2.3.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Type

(2017-2022)

2.4 Hospital-acquired Pneumonia(HAP) Drugs Segment by Application

- 2.4.1 Hospitals
- 2.4.2 Clinics

2.4.3 Other

2.5 Hospital-acquired Pneumonia(HAP) Drugs Sales by Application

2.5.1 Global Hospital-acquired Pneumonia(HAP) Drugs Sale Market Share by Application (2017-2022)

2.5.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue and Market Share by



Application (2017-2022)

2.5.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Application (2017-2022)

3 GLOBAL HOSPITAL-ACQUIRED PNEUMONIA(HAP) DRUGS BY COMPANY

3.1 Global Hospital-acquired Pneumonia(HAP) Drugs Breakdown Data by Company3.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Sales by Company(2020-2022)

3.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Company (2020-2022)

3.2 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Revenue by Company (2020-2022)

3.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Company (2020-2022)

3.2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Company (2020-2022)

3.3 Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Company

3.4 Key Manufacturers Hospital-acquired Pneumonia(HAP) Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Hospital-acquired Pneumonia(HAP) Drugs Product Location Distribution

3.4.2 Players Hospital-acquired Pneumonia(HAP) Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR HOSPITAL-ACQUIRED PNEUMONIA(HAP) DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Hospital-acquired Pneumonia(HAP) Drugs Market Size by Geographic Region (2017-2022)

4.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Revenue by Geographic Region

4.2 World Historic Hospital-acquired Pneumonia(HAP) Drugs Market Size by



Country/Region (2017-2022)

4.2.1 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Sales by Country/Region (2017-2022)

4.2.2 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Revenue by Country/Region

4.3 Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Growth

4.4 APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Growth

4.5 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Growth

4.6 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Growth

5 AMERICAS

5.1 Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Country

5.1.1 Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022)

5.1.2 Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022)

5.2 Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Type

5.3 Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Application

- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

6.1 APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Region

6.1.1 APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2022)

6.1.2 APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2022)

6.2 APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Type

- 6.3 APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan



7 EUROPE

- 7.1 Europe Hospital-acquired Pneumonia(HAP) Drugs by Country
- 7.1.1 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022)
- 7.1.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022)
- 7.2 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Type
- 7.3 Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs by Country

8.1.1 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022)

8.1.2 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022)

8.2 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Type8.3 Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales byApplication

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS



10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Hospital-acquired Pneumonia(HAP) Drugs

10.3 Manufacturing Process Analysis of Hospital-acquired Pneumonia(HAP) Drugs

10.4 Industry Chain Structure of Hospital-acquired Pneumonia(HAP) Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Hospital-acquired Pneumonia(HAP) Drugs Distributors
- 11.3 Hospital-acquired Pneumonia(HAP) Drugs Customer

12 WORLD FORECAST REVIEW FOR HOSPITAL-ACQUIRED PNEUMONIA(HAP) DRUGS BY GEOGRAPHIC REGION

12.1 Global Hospital-acquired Pneumonia(HAP) Drugs Market Size Forecast by Region

12.1.1 Global Hospital-acquired Pneumonia(HAP) Drugs Forecast by Region (2023-2028)

12.1.2 Global Hospital-acquired Pneumonia(HAP) Drugs Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Hospital-acquired Pneumonia(HAP) Drugs Forecast by Type
- 12.7 Global Hospital-acquired Pneumonia(HAP) Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Pfizer

- 13.1.1 Pfizer Company Information
- 13.1.2 Pfizer Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.1.3 Pfizer Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.1.4 Pfizer Main Business Overview
- 13.1.5 Pfizer Latest Developments
- 13.2 GlaxoSmithKline





- 13.2.1 GlaxoSmithKline Company Information
- 13.2.2 GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Product Offered
- 13.2.3 GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue,

Price and Gross Margin (2020-2022)

- 13.2.4 GlaxoSmithKline Main Business Overview
- 13.2.5 GlaxoSmithKline Latest Developments

13.3 Merck

- 13.3.1 Merck Company Information
- 13.3.2 Merck Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.3.3 Merck Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Merck Main Business Overview

13.3.5 Merck Latest Developments

13.4 Mylan

- 13.4.1 Mylan Company Information
- 13.4.2 Mylan Hospital-acquired Pneumonia(HAP) Drugs Product Offered
- 13.4.3 Mylan Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.4.4 Mylan Main Business Overview
 - 13.4.5 Mylan Latest Developments

13.5 Novartis

- 13.5.1 Novartis Company Information
- 13.5.2 Novartis Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.5.3 Novartis Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.5.4 Novartis Main Business Overview
- 13.5.5 Novartis Latest Developments
- 13.6 Teva Pharmaceutical Industries
- 13.6.1 Teva Pharmaceutical Industries Company Information

13.6.2 Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.6.4 Teva Pharmaceutical Industries Main Business Overview
- 13.6.5 Teva Pharmaceutical Industries Latest Developments

13.7 AstraZeneca

- 13.7.1 AstraZeneca Company Information
- 13.7.2 AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Product Offered
- 13.7.3 AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price



and Gross Margin (2020-2022)

13.7.4 AstraZeneca Main Business Overview

13.7.5 AstraZeneca Latest Developments

13.8 Arsanis

13.8.1 Arsanis Company Information

13.8.2 Arsanis Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.8.3 Arsanis Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Arsanis Main Business Overview

13.8.5 Arsanis Latest Developments

13.9 Combioxin

13.9.1 Combioxin Company Information

13.9.2 Combioxin Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.9.3 Combioxin Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Combioxin Main Business Overview

13.9.5 Combioxin Latest Developments

13.10 Shinogi

13.10.1 Shinogi Company Information

13.10.2 Shinogi Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.10.3 Shinogi Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Shinogi Main Business Overview

13.10.5 Shinogi Latest Developments

13.11 Sun Pharmaceutical Industries

13.11.1 Sun Pharmaceutical Industries Company Information

13.11.2 Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.11.3 Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Sun Pharmaceutical Industries Main Business Overview

13.11.5 Sun Pharmaceutical Industries Latest Developments

13.12 The Medicines Company

13.12.1 The Medicines Company Company Information

13.12.2 The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.12.3 The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 The Medicines Company Main Business Overview



13.12.5 The Medicines Company Latest Developments

13.13 Theravance Biopharma

13.13.1 Theravance Biopharma Company Information

13.13.2 Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Product Offered

13.13.3 Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Theravance Biopharma Main Business Overview

13.13.5 Theravance Biopharma Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

Table 1. Hospital-acquired Pneumonia(HAP) Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions) Table 2. Hospital-acquired Pneumonia(HAP) Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions) Table 3. Major Players of Antibacterial Table 4. Major Players of Antiviral Table 5. Major Players of Antifungal Table 6. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs) Table 7. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017 - 2022)Table 8. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Type (2017-2022) & (\$ million) Table 9. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2022) Table 10. Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Type (2017-2022) & (USD/Pcs) Table 11. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs) Table 12. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022) Table 13. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Application (2017 - 2022)Table 14. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application (2017-2022) Table 15. Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Application (2017-2022) & (USD/Pcs) Table 16. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Company (2020-2022) & (K Pcs) Table 17. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Company (2020-2022) Table 18. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Company (2020-2022) (\$ Millions) Table 19. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Company (2020-2022)



Table 20. Global Hospital-acquired Pneumonia(HAP) Drugs Sale Price by Company (2020-2022) & (USD/Pcs) Table 21. Key Manufacturers Hospital-acquired Pneumonia(HAP) Drugs Producing Area Distribution and Sales Area Table 22. Players Hospital-acquired Pneumonia(HAP) Drugs Products Offered Table 23. Hospital-acquired Pneumonia(HAP) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022) Table 24. New Products and Potential Entrants Table 25. Mergers & Acquisitions, Expansion Table 26. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Geographic Region (2017-2022) & (K Pcs) Table 27. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share Geographic Region (2017-2022) Table 28. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Geographic Region (2017-2022) & (\$ millions) Table 29. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Geographic Region (2017-2022) Table 30. Global Hospital-acquired Pneumonia(HAP) Drugs Sales by Country/Region (2017-2022) & (K Pcs) Table 31. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country/Region (2017-2022) Table 32. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country/Region (2017-2022) & (\$ millions) Table 33. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country/Region (2017-2022) Table 34. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs) Table 35. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country (2017-2022) Table 36. Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (\$ Millions) Table 37. Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country (2017-2022) Table 38. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs) Table 39. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2022) Table 40. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales by Application

(2017-2022) & (K Pcs)



Table 41. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022)

Table 42. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2017-2022) & (K Pcs)

Table 43. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2017-2022)

Table 44. APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue by Region (2017-2022) & (\$ Millions)

Table 45. APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Region (2017-2022)

Table 46. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 47. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2022)

Table 48. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 49. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022)

Table 50. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)

Table 51. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country (2017-2022)

Table 52. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue by Country (2017-2022) & (\$ Millions)

Table 53. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country (2017-2022)

Table 54. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 55. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2022)

Table 56. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 57. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Country (2017-2022) & (K Pcs)

Table 59. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue by



Country (2017-2022) & (\$ Millions)

Table 61. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 63. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 65. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022)

 Table 66. Key Market Drivers & Growth Opportunities of Hospital-acquired

Pneumonia(HAP) Drugs

Table 67. Key Market Challenges & Risks of Hospital-acquired Pneumonia(HAP) Drugs

Table 68. Key Industry Trends of Hospital-acquired Pneumonia(HAP) Drugs

 Table 69. Hospital-acquired Pneumonia(HAP) Drugs Raw Material

- Table 70. Key Suppliers of Raw Materials
- Table 71. Hospital-acquired Pneumonia(HAP) Drugs Distributors List

Table 72. Hospital-acquired Pneumonia(HAP) Drugs Customer List

Table 73. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 74. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Forecast by Region

Table 75. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 76. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 78. Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 79. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 80. APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 81. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 82. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Country (2023-2028) & (\$ millions)



Table 83. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 84. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 85. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Type (2023-2028) & (K Pcs)

Table 86. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 88. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Forecast by Application (2023-2028) & (K Pcs)

Table 90. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 92. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share Forecast by Application (2023-2028)

Table 93. Pfizer Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. Pfizer Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 95. Pfizer Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$

Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 96. Pfizer Main Business

Table 97. Pfizer Latest Developments

 Table 98. GlaxoSmithKline Basic Information, Hospital-acquired Pneumonia(HAP)

 Device Manufacturing Data Cales Area and Its Caren stitutes

Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 100. GlaxoSmithKline Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs),

Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 101. GlaxoSmithKline Main Business

Table 102. GlaxoSmithKline Latest Developments

Table 103. Merck Basic Information, Hospital-acquired Pneumonia(HAP) Drugs

Manufacturing Base, Sales Area and Its Competitors

Table 104. Merck Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 105. Merck Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)



Table 106. Merck Main Business Table 107. Merck Latest Developments Table 108. Mylan Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors Table 109. Mylan Hospital-acquired Pneumonia(HAP) Drugs Product Offered Table 110. Mylan Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022) Table 111. Mylan Main Business Table 112. Mylan Latest Developments Table 113. Novartis Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors Table 114. Novartis Hospital-acquired Pneumonia(HAP) Drugs Product Offered Table 115. Novartis Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022) Table 116. Novartis Main Business Table 117. Novartis Latest Developments Table 118. Teva Pharmaceutical Industries Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors Table 119. Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Offered Table 120. Teva Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022) Table 121. Teva Pharmaceutical Industries Main Business Table 122. Teva Pharmaceutical Industries Latest Developments Table 123. AstraZeneca Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors Table 124. AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Product Offered Table 125. AstraZeneca Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022) Table 126. AstraZeneca Main Business Table 127. AstraZeneca Latest Developments Table 128. Arsanis Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors Table 129. Arsanis Hospital-acquired Pneumonia(HAP) Drugs Product Offered Table 130. Arsanis Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022) Table 131. Arsanis Main Business

 Table 132. Arsanis Latest Developments

Table 133. Combioxin Basic Information, Hospital-acquired Pneumonia(HAP) Drugs



Manufacturing Base, Sales Area and Its Competitors

Table 134. Combioxin Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 135. Combioxin Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs),

Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 136. Combioxin Main Business

Table 137. Combioxin Latest Developments

Table 138. Shinogi Basic Information, Hospital-acquired Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Shinogi Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 140. Shinogi Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue

(\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 141. Shinogi Main Business

Table 142. Shinogi Latest Developments

 Table 143. Sun Pharmaceutical Industries Basic Information, Hospital-acquired

Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 144. Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 145. Sun Pharmaceutical Industries Hospital-acquired Pneumonia(HAP) Drugs Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Sales (K FCS), Revenue (\$ Willion), Frice (USD/FCS) and Gross Wargin (202

 Table 146. Sun Pharmaceutical Industries Main Business

 Table 147. Sun Pharmaceutical Industries Latest Developments

 Table 148. The Medicines Company Basic Information, Hospital-acquired

Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 149. The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 150. The Medicines Company Hospital-acquired Pneumonia(HAP) Drugs Sales

(K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

 Table 151. The Medicines Company Main Business

Table 152. The Medicines Company Latest Developments

Table 153. Theravance Biopharma Basic Information, Hospital-acquired

Pneumonia(HAP) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 154. Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Product Offered

Table 155. Theravance Biopharma Hospital-acquired Pneumonia(HAP) Drugs Sales (K

Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 156. Theravance Biopharma Main Business

Table 157. Theravance Biopharma Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Hospital-acquired Pneumonia(HAP) Drugs
- Figure 2. Hospital-acquired Pneumonia(HAP) Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Growth Rate 2017-2028 (K Pcs)
- Figure 7. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Hospital-acquired Pneumonia(HAP) Drugs Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Antibacterial
- Figure 10. Product Picture of Antiviral
- Figure 11. Product Picture of Antifungal
- Figure 12. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Type in 2021
- Figure 13. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Type (2017-2022)
- Figure 14. Hospital-acquired Pneumonia(HAP) Drugs Consumed in Hospitals
- Figure 15. Global Hospital-acquired Pneumonia(HAP) Drugs Market: Hospitals (2017-2022) & (K Pcs)
- Figure 16. Hospital-acquired Pneumonia(HAP) Drugs Consumed in Clinics
- Figure 17. Global Hospital-acquired Pneumonia(HAP) Drugs Market: Clinics (2017-2022) & (K Pcs)
- Figure 18. Hospital-acquired Pneumonia(HAP) Drugs Consumed in Other
- Figure 19. Global Hospital-acquired Pneumonia(HAP) Drugs Market: Other (2017-2022) & (K Pcs)
- Figure 20. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Application (2017-2022)
- Figure 21. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Application in 2021
- Figure 22. Hospital-acquired Pneumonia(HAP) Drugs Revenue Market by Company in 2021 (\$ Million)
- Figure 23. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Company in 2021



Figure 24. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Geographic Region (2017-2022)

Figure 25. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Geographic Region in 2021

Figure 26. Global Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region (2017-2022)

Figure 27. Global Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country/Region in 2021

Figure 28. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales 2017-2022 (K Pcs)

Figure 29. Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue 2017-2022 (\$ Millions)

Figure 30. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales 2017-2022 (K Pcs)

Figure 31. APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue 2017-2022 (\$ Millions)

Figure 32. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales 2017-2022 (K Pcs)

Figure 33. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue 2017-2022 (\$ Millions)

Figure 34. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales 2017-2022 (K Pcs)

Figure 35. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue 2017-2022 (\$ Millions)

Figure 36. Americas Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country in 2021

Figure 37. Americas Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country in 2021

Figure 38. United States Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions)

Figure 39. Canada Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions)

Figure 40. Mexico Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions)

Figure 41. Brazil Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions)

Figure 42. APAC Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Region in 2021

Figure 43. APAC Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Regions in 2021

Figure 44. China Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth



2017-2022 (\$ Millions) Figure 45. Japan Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 46. South Korea Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 47. Southeast Asia Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 48. India Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 49. Australia Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 50. Europe Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country in 2021 Figure 51. Europe Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country in 2021 Figure 52. Germany Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 53. France Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 54. UK Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 55. Italy Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 56. Russia Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 57. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Sales Market Share by Country in 2021 Figure 58. Middle East & Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Market Share by Country in 2021 Figure 59. Egypt Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 60. South Africa Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 61. Israel Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 62. Turkey Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions) Figure 63. GCC Country Hospital-acquired Pneumonia(HAP) Drugs Revenue Growth 2017-2022 (\$ Millions)



Figure 64. Manufacturing Cost Structure Analysis of Hospital-acquired Pneumonia(HAP) Drugs in 2021

Figure 65. Manufacturing Process Analysis of Hospital-acquired Pneumonia(HAP) Drugs

Figure 66. Industry Chain Structure of Hospital-acquired Pneumonia(HAP) Drugs

- Figure 67. Channels of Distribution
- Figure 68. Distributors Profiles



I would like to order

Product name: Global Hospital-acquired Pneumonia(HAP) Drugs Market Growth 2022-2028 Product link: <u>https://marketpublishers.com/r/GDEF950EF246EN.html</u>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/GDEF950EF246EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970